Altimmune, Inc. (NASDAQ: ALT) reported Q3 EPS of ($0.39), $0.06 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $362 thousand versus the consensus estimate of $857 million.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.